IQM
1.7.2021 13:02:09 CEST | Business Wire | Press release
IQM Quantum Computers (IQM) expands its operations to Spain, creating a subsidiary in Bilbao. This operation has been supported by Basque local administration via Provincial Council of Bizkaia and Bilbao City Hall.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005046/en/
With its Spain operations, IQM aims to tap into another hotspot for quantum computing in addition to its Finland and Germany offices. IQM Spain will collaborate closely with the local research community, quantum experts from academia and the industry to build a vibrant Spanish and European quantum ecosystem. IQM with its international partner network will also connect the Spanish quantum ecosystem to the global quantum network.
“QUTIS Center in University of the Basque Country Bilbao has outstanding experience and experts in quantum computation and simulation, quantum control, quantum sensing and other areas. Today’s announcement signals our commitment to accelerate the success of our application-specific quantum computers, and aggressively develop quantum finance offerings for our customers worldwide,” said Jan Goetz, CEO at IQM. “Local Public Administration, via Beaz and Bilbao Ekintza, have been extremely supportive and are committed to attracting best talent and growth companies. We look forward to working with their team to grow our Co-Design offering from Spain and deliver it globally.”
The technical goal for this Spanish subsidiary is to create a quantum finance Co-Design hub that tightens the interaction between hardware and software to solve problems in finance. In particular, IQM Spain will develop an application-specific approach where quantum software integrates closely with a suitably designed quantum hardware with novel quantum architectures. Combined with IQM's hardware experts and go-to market teams in Finland and Germany, IQM will be able to deliver this offering to global customers. This approach accelerates the development of useful quantum solutions for specialized financial applications and will establish Spain and Europe as the leaders for quantum finance.
Last year, IQM had also entered into a research agreement with the University of the Basque Country (UPV/EHU) in Bilbao, a collaboration led by Dr. Jorge Casanova (Ramón y Cajal and Ikerbasque researcher at UPV/EHU) and includes Dr. Mikel Sanz (Ikerbasque Researcher at UPV/EHU) and Prof. Xi Chen (Professor at Shanghai University and Ramon y Cajal researcher at UPV/EHU).
Ms. Olatz Goitia, General Manager of Beaz, said, “We work to turn the territory into an innovation hub of international reference, and to this end, the retention and attraction of talent and entrepreneurship and companies like IQM is key.”
Mr. Javier Garcinuño Zabala, General Manager of Bilbao Ekintza, said, “We’re pleased to see European growth companies like IQM start their Spanish operations in Bilbao. Our BIG Bilbao entrepreneurship centre will support their local operations and Bilbao Ekintza will also collaborate with IQM on joint projects in Bilbao’s strategic economic sectors.”
About Beaz:
Beaz is a public company of the Provincial Council of Bizkaia whose objective is to support companies and entrepreneurs in their efforts to create new projects, innovate and internationalize. A goal that is in line with that of the Regional Department of Economic Promotion, to which Beaz reports directly: to contribute to the growth of economic activity and the creation of qualified employment.
About Bilbao Ekintza:
Bilbao Ekintza is a public company of Bilbao City Hall that develops the municipal powers in the field of economic development, promotion of Bilbao and its events as a tourist destination and business promotion, both from the point of view of the attraction, creation and growth of companies and the improvement of opportunities for access to employment.
https://www.bilbaoekintza.eus/en
About IQM Quantum Computers:
IQM is the European leader in superconducting quantum computers, headquartered in Espoo, Finland. Since its inception in 2018, IQM has grown to 110+ employees and established a subsidiary in Munich, Germany, to lead the Co-Design approach.
IQM delivers on-premises quantum computers for research laboratories and supercomputing centers and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific Co-Design approach.
IQM is building Finland’s first commercial quantum computer with VTT, and an IQM-led consortium was awarded € 12.4 Million in February 2021 to commercialize application-specific quantum processors by the German Ministry of Education and Research.
For more information, visit www.meetiqm.com .
Registered office:
IQM Finland Oy
Keilaranta 19
02150 Espoo
Finland
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom